| |
NEXMED CONFIRMS DATA PRESENTATIONS ON ANTI-FUNGAL PRODUCT AT TWO PHARMA CONFERENCES
-Q1 Results To Be Reported on Monday, May 12, 2008-
East Windsor, NJ, May 8, 2008 -- NexMed, Inc. (Nasdaq: NEXM), a developer of innovative products based on the NexACT® drug delivery technology, today confirmed that eight presentations on NM100060, a topical treatment for onychomycosis (nail fungus) licensed to Novartis, will be made at two conferences in July and September 2008, as follows:
• Four posters will be presented at The 2008 Annual Scientific Meeting of the American Podiatric Medical Association (APMA) being held at the Hilton Hawaiian Village and Convention Center in Honolulu, Hawaii, July 24-28, 2008, and;
• Four posters will be presented at The 17th Congress of the European Academy of Dermatology, EADV Conference being held at the Palais Des Congres 2 in Paris, France, September 17-21, 2008
All of the presentations are sponsored by Novartis and NexMed.
NM100060 is a topical application of Lamisil® (terbinafine hydrochloride), formulated with terbinafine and NexMed’s patented NexACT technology that is being developed for the treatment of onychomycosis. NexMed entered into an exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060.
Conference Call
NexMed will file its 10-Q for the quarter ended March 31, 2008 on May 12, 2008. The Company’s 2008 first quarter conference call is scheduled for Tuesday, May 13, 2008 at 10:00 a.m. EST. At that time, management will review 2008 first quarter financial results, as well as the status of its products in the pipeline. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 284928 are both required for playback. The conference call will also be Webcast live at URL http://www.investorcalendar.com/IC/CEPage.asp?ID=129703. The Webcast replay will be available for three months.
About NexMed
NexMed, Inc. is leveraging its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NM100060 is currently in pivotal Phase 3 trials in the U.S. and Europe. In November 2007, NexMed’s New Drug Application for its alprostadil treatment for erectile dysfunction was accepted for review by the FDA and the Company signed a U.S. licensing agreement for the product with Warner Chilcott. The Company’s New Drug Submission for the product was accepted for review by Health Canada in February 2008. NexMed's pipeline also includes a Phase 2 treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.
# # #
Company Contact:
Mark Westgate, CFO
NexMed, Inc.
(609) 371-8123, ext: 159
mwestgate@nexmed.com
Investor Relations:
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
|
|
